Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-Dose Decitabine Plus Anti-PD-1 for R/R DLBCL with CNS Involvement
NCT05816746Phase 2Recruiting
- Sponsor
- Chinese PLA General Hospital
- Start
- May 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine in diffuse large B-cell lymphoma (DLBCL), sponsored by Chinese PLA General Hospital. Started May 2023; status: recruiting.
02
Drugs
decitabine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT05816746.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05816746.